Practice Parameter: Corticosteroid treatment of Duchenne dystrophy - Report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society

Neurology

Volumn 64, Issue 1, 2005, Pages 13-20

  Moxley III, R T ^a   Ashwal, S ^b   Pandya, S ^a   Connolly, A ^d   Florence, J ^e   Mathews, K ^f   Baumbach, L ^g   McDonald, C ^c   Sussman, M ^h   Wade, C ⁱ  

^a UNIVERSITY OF ROCHESTER   (United States)

^b LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Department of Neurology ^*  (United States)

^e WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF IOWA   (United States)

^g BAYLOR COLLEGE OF MEDICINE   (United States)

^h SHRINERS HOSPITAL FOR CHILDREN   (United States)

ⁱ UNIVERSITY OF WYOMING   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; DEFLAZACORT; PREDNISOLONE;

ACNE; BEHAVIOR DISORDER; CATARACT; CLINICAL TRIAL; CORTICOSTEROID THERAPY; DISEASE COURSE; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG MEGADOSE; DUCHENNE MUSCULAR DYSTROPHY; EVIDENCE BASED MEDICINE; GASTROINTESTINAL DISEASE; HEALTH CARE QUALITY; HUMAN; LONG TERM CARE; LOW DRUG DOSE; LUNG FUNCTION; MOBILIZATION; MOON FACE; MUSCLE FUNCTION; MUSCLE STRENGTH; MUSCLE WEAKNESS; PATIENT CARE; PHYSICAL PERFORMANCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; TREATMENT OUTCOME; URINARY EXCRETION; WEIGHT GAIN;

EID: 19944427852     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000148485.00049.B7     Document Type: Review

References (49)

1. Hoffman EP. Dystrophinopathies. In: Karpati G, Hilton-Jones D, Griggs R, eds. Disorders of voluntary muscle. Cambridge: Cambridge University Press, 2001:385-432.
2. O'Brien KF, Kunkel LM. Dystrophin and muscular dystrophy: past, present, and future. Mol Genet Metab 2001;74:75-88.
3. Wong BL, Christopher C. Corticosteroids in Duchenne dystrophy: a reappraisal. J Child Neurol 2002;17:183-190.
4. Brooke MH, Fenichel GM, Griggs RC, et al. Clinical investigation in Duchenne dystrophy: 2. Determination of the "power" of therapeutic trials based on the natural history. Muscle Nerve 1983;6:91-103.
5. Brooke MH, Fenichel GM, Griggs RC, et al. Duchenne dystrophy: patterns of clinical progression and effects of supportive therapy. Neurology 1989;39:475-481.
6. Eagle M, Baudouin SV, Chandler C, Giddings DR, Bullock R, Bushby K. Survival in Duchenne dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation. Neuromusc Disord 2002;12:926-929.
7. Sussman M. Duchenne dystrophy. J Am Acad Orthop Surg 2002;10:138-151.
8. Khan MA. Corticosteroid therapy in Duchenne dystrophy. J Neurol Sci 1993;120:8-14.
9. Muntoni F, Fisher I, Morgan J, et al. Steroids in Duchenne dystrophy: from clinical trials to genomic research. Neuromusc Disord 2002;12:S162.
10. Kissel JT, Burrow KL, Rammohan KW, et al. Mononuclear cell analysis of muscle biopsies in prednisone-treated and untreated Duchenne dystrophy. CIDD Study Group. Neurology 1991;41:667-672.
11. Cai B, Spencer MJ, Nakamura G, et al. Eosinophilia of dystrophin-deficient muscle is promoted by perforin-mediated cytotoxicity by T cell effectors. Am J Pathol 2000;156:1789-1796.
12. Metzinger L, Passaquin AC, Leijendekker WJ, et al. Modulation by prednisolone of calcium handling in skeletal muscle cells. Br J Pharmacol 1995;116:2811-2816.
13. Passaquin AC, Lhote P, Ruegg UT. Calcium influx inhibition by steroids and analogs in C2C12 skeletal muscle cells. Br J Pharmacol 1998;124:1751-1759.
14. Anderson JE, Weber M, Vargas C. Deflazacort increases laminin expression and myogenic repair, and induces early persistent functional gain in mdx mouse muscular dystrophy. Cell Transplant 2000;9:551-564.
15. Kojima S, Takagi A, Watanabe T. Effect of prednisolone on apoptosis and cellular infiltration in mdx mouse muscle. Rinsho Shinkeigaku 1999;39:1109-1113.
16. Hardiman O, Sklar RM, Brown RH Jr. Methylprednisolone selectively affects dystrophin expression in human muscle cultures. Neurology 1993;43:342-345.
17. Fukudome T, Shibuya N, Yoshimura T, Eguchi K. Short-term effects of prednisolone on neuromuscular transmission in the isolated mdx mouse diaphragm. Tohoku J Exp Med 2000;192:211-217.
18. Jacobs SC, Bootsma AL, Willems PW, et al. Prednisone can protect against exercise-induced muscle damage. J Neurol 1996;243:410-416.
19. Takagi A, Watanabe T, Kojima S, Endo Y. Effect of long-term administration of prednisolone on serum creatine kinase and muscle pathology of mdx mouse. Rinsho Shinkeigaku 1998;38:724-728.
20. Moxley RT III, Lorenson M, Griggs RC, et al. Decreased breakdown of muscle protein after prednisone therapy in Duchenne dystrophy. J Neurol Sci 1990;98(suppl):421.
21. Kawai H, Adachi K, Nishida Y, et al. Decrease in urinary excretion of 3-methylhistidine by patients with Duchenne dystrophy during glucocorticoid treatment. J Neurol 1993;240:181-186.
22. Rifai Z, Welle S, Moxley RT III, et al. Effect of prednisone on protein metabolism in Duchenne dystrophy. Am J Physiol 1995;268:E67-E74.
23. McIntosh L, Granberg KE, Briere KM, Anderson JE. Nuclear magnetic resonance spectroscopy study of muscle growth, mdx dystrophy and glucocorticoid treatments: correlation with repair. NMR Biomed 1998;11:1-10.
24. Griggs RC, Moxley RT III, Mendell JR, et al. Duchenne dystrophy: randomized, controlled trial of prednisone (18 months) and azathioprine (12 months) Neurology 1993;43:520-527.
25. Mendell JR, Moxley RT III, Griggs RC, et al. Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy. N Engl J Med 1989;320:1592-1597.
26. Fenichel GM, Mendell JR, Moxley RT III, et al. A comparison of daily and alternate-day prednisone therapy in the treatment of Duchenne dystrophy. Arch Neurol 1991;48:575-579.
27. Griggs RC, Moxley RT III, Mendell JR, et al. Prednisone in Duchenne dystrophy. A randomized, controlled trial defining the time course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Arch Neurol 1991;48:383-388.
28. Rahman MM, Hannan MA, Mondol BA, Bhoumick NB, Haque A. Prednisolone in Duchenne dystrophy. Bangladesh Med Res Counc Bull 2001;27:38-42.
29. Backman E, Henriksson KG. Low-dose prednisolone treatment in Duchenne and Becker muscular dystrophy. Neuromusc Disord 1995;5:233-241.
30. Siegel IM, Miller JE, Ray RD. Failure of corticosteroid in the treatment of Duchenne (pseudo-hypertrophic) muscular dystrophy. Report of a clinically matched three year double-blind study. Ill Med J 1974;145:32-33.
31. Fenichel GM, Florence JM, Pestronk A, et al. Long-term benefit from prednisone therapy in Duchenne dystrophy. Neurology 1991;41:1874-1877.
32. Biggar WD, Gingras M, Fehlings DL, et al. Deflazacort treatment of Duchenne dystrophy. J Pediatr 2001;138:45-50.
33. Drachman DB, Toyka KV, Myer E. Prednisone in Duchenne dystrophy. Lancet 1974;2:1409-1412.
34. DeSilva S, Drachman DB, Mellits D, Kuncl RW. Prednisone treatment in Duchenne dystrophy. Long-term benefit. Arch Neurol 1987;44:818-822.
35. Brooke MH, Fenichel GM, Griggs RC, et al. Clinical investigation of Duchenne dystrophy. Interesting results in a trial of prednisone. Arch Neurol 1987;44:812-817.
36. Sansome A, Royston P, Dubowitz V. Steroids in Duchenne dystrophy; pilot study of a new low-dosage schedule. Neuromusc Disord 1993;3:567-569.
37. Carter GT, McDonald CM. Preserving function in Duchenne dystrophy with long-term pulse prednisone therapy. Am J Phys Med Rehabil 2000;79:455-458.
38. Kinali M, Mercuri E, Main M, et al. An effective, low-dosage, intermittent schedule of prednisolone in the long-term treatment of early cases of Duchenne dystrophy. Neuromusc Disord 2002;12(suppl 1):S169-S174.
39. Dubowitz V, Kinali M, Main M, et al. Remission of clinical signs in early Duchenne dystrophy on intermittent low-dosage prednisolone therapy. Eur J Paediatr Neurol 2002;6:153-159.
40. Connolly AM, Schierbecker J, Renna R, Florence J. High dose weekly oral prednisone improves strength in boys with Duchenne dystrophy. Neuromusc Disord 2002;12:917-925.
41. Merlini L, Cicognani A, Malaspina E, et al. Early prednisone treatment in Duchenne dystrophy. Muscle Nerve 2003;27:222-227.
42. Markham A, Bryson HM. Deflazacort. A review of its pharmacological properties and therapeutic efficacy. Drugs 1995;50:317-333.
43. Mesa LE, Dubrovsky AL, Corderi J, et al. Steroids in Duchenne dystrophy-deflazacort trial. Neuromusc Disord 1991;1:261-266.
44. Angelini C, Pegoraro E, Turella E, et al. Deflazacort in Duchenne dystrophy: study of long-term effect. Muscle Nerve 1994;17:386-391.
45. Reitter B. Deflazacort vs. prednisone in Duchenne dystrophy: trends of an ongoing study. Brain Dev 1995;17(suppl):39-43.
46. Reitter B. 75th European Neuromuscular Centre International Workshop: 2nd workshop on the treatment of muscular dystrophy, 10-12 December, 1999, Naarden, the Netherlands. Neuromusc Disord 2000;10:313-320.
47. Bonifati MD, Ruzza G, Bonometto P, et al. A multicenter, double-blind, randomized trial of deflazacort versus prednisone in Duchenne dystrophy. Muscle Nerve 2000;23:1344-1347.
48. Schara U, Mortier J, Mortier W. Long term steroid therapy in Duchenne dystrophy - positive results versus side effects. J Clin Neuromusc Dis 2001;2:179-183.
49. Manzur AY, Kuntzer T, Pike M, Swan A. Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Cochrane Rev 2004;2:1-55.